Search

Your search keyword '"Bushmakin, Andrew G."' showing total 544 results
Start Over Author "Bushmakin, Andrew G."
544 results on '"Bushmakin, Andrew G."'

4. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

Author

Yosipovitch, Gil, Gooderham, Melinda J., Ständer, Sonja, Fonacier, Luz, Szepietowski, Jacek C., Deleuran, Mette, Girolomoni, Giampiero, Su, John C., Bushmakin, Andrew G., Cappelleri, Joseph C., Feeney, Claire, Chan, Gary, Thorpe, Andrew J., Valdez, Hernan, Biswas, Pinaki, Rojo, Ricardo, DiBonaventura, Marco, and Myers, Daniela E.

Published
2024
Full Text
View/download PDF

6. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

Author

Eichenfield, Lawrence F, Yosipovitch, Gil, Gold, Linda F Stein, Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E, Bushmakin, Andrew G, Cappelleri, Joseph C, Olivadoti, Melissa, and Paller, Amy S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Pediatric, Adolescent, Boron Compounds, Bridged Bicyclo Compounds, Heterocyclic, Child, Child, Preschool, Dermatitis, Atopic, Double-Blind Method, Humans, Ointments, Pruritus, Severity of Illness Index, Treatment Outcome, atopic dermatitis, pruritus, therapy-topical, Paediatrics and Reproductive Medicine, Dermatology & Venereal Diseases, Clinical sciences, Paediatrics
Abstract

Background/objectivesCrisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator's Static Global Assessment (ISGA) and Severity of Pruritus Scale (SPS) outcomes in pediatric patients with mild-to-moderate AD.MethodsPatients aged ≥2 years were randomly assigned 2:1 to receive twice-daily crisaborole or vehicle for 28 days. Patients aged 2-17 years were pooled for this analysis. Proportions of patients and time to achieving ISGA success (clear [0] or almost clear [1] with ≥2-grade improvement from baseline), ISGA clear/almost clear, ≥1-grade improvement in ISGA, SPS success (SPS score ≤1 with ≥1-grade improvement), or ≥1-grade improvement in SPS score were analyzed and stratified by baseline ISGA.ResultsAt first postbaseline assessment (day 8), significantly higher proportions of crisaborole- than vehicle-treated patients achieved ISGA success, ISGA clear/almost clear, ≥1-grade ISGA improvement, SPS success, or ≥1-grade improvement in SPS regardless of baseline ISGA. Differences were significantly greater over time for all outcomes for patients with moderate baseline ISGA and numerically greater for those with mild baseline ISGA. Median times to ISGA and SPS outcomes were shorter for crisaborole versus vehicle.ConclusionImprovement in ISGA and SPS outcomes were observed with crisaborole in pediatric patients with mild-to-moderate baseline AD.

Published
2020

8. Validation of the Peak Pruritus‐Numerical Rating Scale in patients with chronic plaque psoriasis: results from a phase 2 study.

Author

Draelos, Zoe D., Bushmakin, Andrew G., Ghosh, Pranab, Xenakis, Jason, and Cappelleri, Joseph C.

Subjects
*INTRACLASS correlation, *TEST validity, *MEDICAL statistics, *QUALITY of life, *REGRESSION analysis
Abstract

Background: Pruritus is a common, bothersome symptom for patients with mild‐to‐moderate plaque psoriasis (PsO), yet no validated scale assesses it in this patient population. We aimed to validate the Peak Pruritus‐Numerical Rating Scale (PP‐NRS) using data from a Phase 2b study investigating the efficacy of brepocitinib in patients with mild‐to‐moderate chronic PsO. Methods: Patients completed the PP‐NRS daily from baseline for the first 2 weeks after the dose administration and subsequently only on visit days. Test–retest reliability (intraclass correlation coefficient [ICC]), construct validity (known group validity and convergent validity), ability to detect change, and meaningful within‐patient change (MWPC) were evaluated using correlation and regression analyses. Results: The PP‐NRS demonstrated acceptable test–retest reliability (ICC: 0.86–0.89). Known‐group evidence demonstrated that PP‐NRS scores could discriminate between different degrees of disease severity. Convergent validity was supported by significant correlation coefficients between the PP‐NRS and Patient Global Assessment (PtGA), Dermatology Life Quality Index, and Psoriasis Symptom Inventory, which generally exceeded 0.50. The ability to detect change was evidenced by an approximately linear relationship between changes in PP‐NRS and Physician Global Assessment or PtGA of psoriasis scores. The value of 2.8 was determined as the MWPC for the PP‐NRS. Conclusions: PP‐NRS is a reliable, practical test for assessing pruritus in mild‐to‐moderate PsO clinical trials. ClinicalTrials.gov identifier NCT03850483. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. 542 - Validation of the skin pain numerical rating scale of the Pruritus and Symptoms Assessment for Atopic Dermatitis for adults and adolescents with moderate-to-severe atopic dermatitis

Author

Silverberg, Jonathan I, primary, Ständer, Sonja, additional, Kim, Brian S, additional, Bewley, Anthony, additional, Misery, Laurent, additional, Vestergaard, Christian, additional, Gooderham, Melinda J, additional, Bushmakin, Andrew G, additional, Cappelleri, Joseph C, additional, Güler, Erman, additional, Alderfer, Justine, additional, Watkins, Melissa, additional, Selfridge, Andrew, additional, and Myers, Daniela E, additional

Published
2024
Full Text
View/download PDF

30. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

Author

Yosipovitch, Gil, primary, Gooderham, Melinda J., additional, Ständer, Sonja, additional, Fonacier, Luz, additional, Szepietowski, Jacek C., additional, Deleuran, Mette, additional, Girolomoni, Giampiero, additional, Su, John C., additional, Bushmakin, Andrew G., additional, Cappelleri, Joseph C., additional, Feeney, Claire, additional, Chan, Gary, additional, Thorpe, Andrew J., additional, Valdez, Hernan, additional, Biswas, Pinaki, additional, Rojo, Ricardo, additional, DiBonaventura, Marco, additional, and Myers, Daniela E., additional

Published
2023
Full Text
View/download PDF

31. Relationships of Work Productivity and Activity Impairment With Patient‐Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials.

Author

Magrey, Marina, Wei, James Cheng‐Chung, Yndestad, Arne, Bushmakin, Andrew G., Cappelleri, Joseph C., Dina, Oluwaseyi, and Deodhar, Atul

Subjects
LABOR productivity, ANKYLOSING spondylitis, PATIENT reported outcome measures, QUALITY of life, VISUAL analog scale
Abstract

Objective: We examined the relationships of work productivity and activity impairment with key patient‐reported outcomes (PROs) assessing pain, disease activity, and health‐related quality of life (HRQoL) in patients with ankylosing spondylitis (AS). Methods: This post hoc analysis pooled available data from baseline to end of the double‐blind phase of phase 2 and 3 placebo‐controlled tofacitinib trials in patients with active AS. A repeated‐measures longitudinal model assessed the relationships (linear or nonlinear) between Work Productivity and Activity Impairment questionnaire in Spondyloarthritis (WPAI:SpA) domains (absenteeism, activity impairment, presenteeism, and productivity loss) as outcomes and key PROs (total back pain, nocturnal spinal pain, Patient Global Assessment of Disease Activity, AS Quality of Life, EuroQol 5‐Dimension 3‐Level [EQ‐5D‐3L], and EQ‐5D Visual Analog Scale [EQ‐5D‐VAS]) as predictors. Results: Data from 330 to 475 patients were available, depending on the analysis. Relationships between WPAI:SpA domains and PROs were approximately linear. The worst PRO scores were associated with a decline in patients' work capacity (measured by activity impairment, presenteeism, and productivity loss [>65%]); the best scores were associated with improvements in WPAI:SpA domains (8%–23%). Incremental PRO improvements were associated with improvement of activity impairment, presenteeism, and productivity loss. Relationships between absenteeism and PROs were the weakest, owing to absenteeism being low in the study population. Conclusion: Evidence of linear relationships between work productivity and activity impairment with patient‐reported pain, disease activity, and HRQoL was observed. Interventions to control pain and disease activity and improve HRQoL are therefore likely to improve work productivity and reduce activity impairment in patients with AS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Relationships of Work Productivity and Activity Impairment With Patient‐ReportedOutcomes in Ankylosing Spondylitis: Results From Two Trials

Author

Magrey, Marina, Wei, James Cheng‐Chung, Yndestad, Arne, Bushmakin, Andrew G., Cappelleri, Joseph C., Dina, Oluwaseyi, and Deodhar, Atul

Abstract

We examined the relationships of work productivity and activity impairment with key patient‐reported outcomes (PROs) assessing pain, disease activity, and health‐related quality of life (HRQoL) in patients with ankylosing spondylitis (AS). This post hoc analysis pooled available data from baseline to end of the double‐blind phase of phase 2 and 3 placebo‐controlled tofacitinib trials in patients with active AS. A repeated‐measures longitudinal model assessed the relationships (linear or nonlinear) between Work Productivity and Activity Impairment questionnaire in Spondyloarthritis (WPAI:SpA) domains (absenteeism, activity impairment, presenteeism, and productivity loss) as outcomes and key PROs (total back pain, nocturnal spinal pain, Patient Global Assessment of Disease Activity, AS Quality of Life, EuroQol 5‐Dimension 3‐Level [EQ‐5D‐3L], and EQ‐5D Visual Analog Scale [EQ‐5D‐VAS]) as predictors. Data from 330 to 475 patients were available, depending on the analysis. Relationships between WPAI:SpA domains and PROs were approximately linear. The worst PRO scores were associated with a decline in patients’ work capacity (measured by activity impairment, presenteeism, and productivity loss [>65%]); the best scores were associated with improvements in WPAI:SpA domains (8%–23%). Incremental PRO improvements were associated with improvement of activity impairment, presenteeism, and productivity loss. Relationships between absenteeism and PROs were the weakest, owing to absenteeism being low in the study population. Evidence of linear relationships between work productivity and activity impairment with patient‐reported pain, disease activity, and HRQoL was observed. Interventions to control pain and disease activity and improve HRQoL are therefore likely to improve work productivity and reduce activity impairment in patients with AS.

Published
2024
Full Text
View/download PDF

41. 350 Examining the relationships among abrocitinib treatment, itch, skin pain and work and activity impairments in patients with atopic dermatitis: a mediation modelling analysis

Author

Silverberg, Jonathan I, primary, Ständer, Sonja, additional, Thyssen, Jacob P, additional, Kim, Brian S, additional, Castro, Carla, additional, Bewley, Anthony, additional, Misery, Laurent, additional, Bushmakin, Andrew G, additional, Cappelleri, Joseph C, additional, Guler, Erman, additional, Alderfer, Justine, additional, Watkins, Melisa, additional, Chan, Gary, additional, and Myers, Daniela E, additional

Published
2023
Full Text
View/download PDF

42. 351 Examining the relationships among abrocitinib treatment, itch, skin pain and dermatology-specific quality of life in patients with atopic dermatitis: a mediation modelling analysis

Author

Silverberg, Jonathan I, primary, Ständer, Sonja, additional, Thyssen, Jacob P, additional, Kim, Brian S, additional, Castro, Carla, additional, Bewley, Anthony, additional, Misery, Laurent, additional, Bushmakin, Andrew G, additional, Cappelleri, Joseph C, additional, Guler, Erman, additional, Alderfer, Justine, additional, Watkins, Melissa, additional, Chan, Gary, additional, and Myers, Daniela E, additional

Published
2023
Full Text
View/download PDF

44. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program

Author

Dubinsky, Marla C., primary, Armuzzi, Alessandro, additional, Gecse, Krisztina B., additional, Ullman, Thomas, additional, Bushmakin, Andrew G., additional, DiBonaventura, Marco, additional, Cappelleri, Joseph C., additional, Connelly, Susan B., additional, Woolcott, John C., additional, and Salese, Leonardo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results